Common Hawthorn for Health & Longevity

Evidence Review created on 11/06/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Hawthorn, Crataegus monogyna, Crataegus oxyacantha, Single-Seed Hawthorn, Oneseed Hawthorn, Whitethorn, Quickthorn, May, Mayblossom, Haw, Hawberry, Hawthorn Leaf and Flower, Hawthorn Berry, Crataegi folium cum flore, Crataegi fructus, WS 1442, Crataegutt

Motivation

Common hawthorn (Crataegus monogyna) is a thorny shrub of the rose family whose leaves, flowers and red berries have long served as a heart tonic in European herbal medicine. Standardized extracts of its leaves and flowers are sold as dietary supplements and, in parts of Europe, as licensed herbal medicines. Interest centers on plant compounds in the leaves and flowers that are thought to strengthen the heartbeat and relax blood vessels.

Hawthorn has been used for heart complaints since antiquity and has been studied in Germany since the 1930s. It draws interest as an inexpensive, widely available option for people with raised blood pressure or mild heart failure, and a large two-year trial in heart failure examined whether it could prevent serious cardiac events.

This review examines the human evidence on common hawthorn for heart function, blood pressure and wider cardiovascular health, together with its risks, drug interactions, product quality problems and practical use, so that health-focused adults can weigh where it fits within a long-term strategy for staying healthy.

Benefits - Risks - Protocol - Conclusion

Overview content that discusses common hawthorn by name and in depth, from a priority platform, clinical reviewers, the leading extract’s trial investigators and independent academic reviewers.

  • Heart Failure - Shayna Sandhaus & Maureen Williams

    Life Extension’s protocol contains a dedicated hawthorn section on procyanidin dosing and heart failure trials; it describes the main survival trial more favorably than that trial’s primary result. Life Extension also sells hawthorn products.

  • Health effects of hawthorn - Dahmer & Scott, 2010

    A concise review for primary-care physicians covering the two main extracts, heart failure trial findings, tolerability and theoretical drug interactions.

  • Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review - Holubarsch et al., 2018

    The most detailed efficacy and safety synthesis for the most-studied extract; all three authors received honoraria from Dr. Willmar Schwabe, the extract’s manufacturer.

  • Hawthorn (Crataegus monogyna Jacq.): A Review of Therapeutic Potential and Applications - Kępińska-Pacelik & Biel, 2026

    A recent narrative review specific to common hawthorn, covering the chemistry of fruit, leaves and flowers and cardiovascular, metabolic and antimicrobial research, most of it preclinical.

  • Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease - Tassell et al., 2010

    An academic narrative review of proposed mechanisms, clinical trials, herb–drug interactions and safety, including a discussion of the retrospective HERB CHF analysis suggesting early heart failure worsening.

Priority experts not listed: Rhonda Patrick’s FoundMyFitness mentions hawthorn only in passing, in a members-only Q&A and in a digest on a multi-ingredient supplement (FoundMyFitness digest); Chris Kresser’s site has a brief passage on hawthorn tea (Chris Kresser article); Peter Attia, Andrew Huberman and Lifespan.io have no hawthorn content. None of these discusses hawthorn in depth.

Grokipedia

Crataegus monogyna

An encyclopedic overview of common hawthorn’s botany, ecology, chemistry and traditional cardiovascular use; useful for species identification and its historical confusion with Crataegus oxyacantha.

Examine

No Examine article on common hawthorn (Crataegus monogyna) exists. Examine covers only a related species:

Chinese Hawthorn

Examine’s page on Crataegus pinnatifida, a different species eaten as food and used in Chinese medicine; its lipid and allergy findings do not transfer directly to common hawthorn leaf-and-flower extracts.

ConsumerLab

No dedicated ConsumerLab article on common hawthorn exists. Hawthorn is discussed only within members-only ConsumerLab answers on blood pressure and cholesterol supplements, and ConsumerLab has not published a laboratory test of hawthorn products.

Systematic Reviews

Systematic reviews and meta-analyses of hawthorn for heart failure, blood pressure and adverse events.

Mechanism of Action

Hawthorn leaf-and-flower extracts contain oligomeric procyanidins (short chains of linked flavonoid units) and flavonoids such as hyperoside, vitexin-rhamnoside and rutin; WS 1442, the most-studied extract, is adjusted to 17.3–20.1% procyanidins (Holubarsch 2018).

  • Stronger contraction: A review reports that in laboratory human heart tissue, the extract increases contractility, likely by inhibiting Na⁺/K⁺-ATPase (the cell-membrane sodium pump that digoxin also blocks), independently of cAMP (cyclic adenosine monophosphate, the messenger used by adrenaline) (Holubarsch 2018).
  • Rhythm stabilization: The same review reports that, unlike digoxin, it lengthens the heart cells’ refractory period (recovery time before the next beat) and reduced reperfusion arrhythmias (irregular rhythms when blood flow returns) in animals (Holubarsch 2018).
  • Vessel relaxation: Per the same review, it activates eNOS (endothelial nitric oxide synthase, the vessel-lining enzyme that produces the vessel-relaxing gas nitric oxide) (Holubarsch 2018).
  • Competing view: In prehypertensive adults (pressure slightly above normal), three doses produced no dose-related change in flow-mediated dilation (artery widening after a cuff is released, a nitric oxide readout), suggesting any blood pressure effect is not nitric oxide-driven (Asher 2012). Inhibition of ACE (angiotensin-converting enzyme, which makes the vessel-constricting hormone angiotensin II) and mild sedation have also been proposed (Szikora 2025).
  • Pharmacological properties: No human half-life, target selectivity, tissue distribution or metabolic pathway has been characterized; a review reports 16–40% absorption of labeled catechins and procyanidins in mice, detectable after one hour (Holubarsch 2018). Flavonoids may affect P-glycoprotein (an intestinal drug-export pump), yet digoxin exposure was unchanged in volunteers (Tankanow 2003).

Historical Context & Evolution

Hawthorn leaves and flowers have been named as heart remedies since the 1st century AD; a review recounts that an 1896 report described 43 heart patients treated with Crataegus oxyacantha, and German research began in the 1930s, leading to German pharmacopoeia inclusion in 1941 (Holubarsch 2018). In Chinese medicine the fruit of a different species, Crataegus pinnatifida, is used mainly as a digestive aid and food.

  • Regulatory acceptance: Germany’s Commission E (the former expert panel on herbal medicines) approved leaf-and-flower extracts for New York Heart Association (NYHA) class II heart failure (symptoms on ordinary activity), per a Cochrane review (Pittler 2008). The European Medicines Agency (EMA) later recognized only traditional use, for nervous heart complaints, mild stress and sleep (EMA monograph).
  • Small trials, then large ones: The review’s 14 small trials, mostly of one manufacturer’s extract (WS 1442), showed better exercise tolerance and symptoms (Pittler 2008). Two larger trials followed: SPICE, whose investigators received honoraria from that manufacturer per their later review (Holubarsch 2018), did not reduce cardiac events, and the National Institutes of Health-funded HERB CHF trial found no functional benefit (Holubarsch 2008; Zick 2009).
  • Current standing: Supporters cite the symptom data and SPICE’s safety record; critics cite null hard outcomes and a post hoc (decided after unblinding) early-worsening signal (Zick 2008). No new large trial has settled the question; attention has shifted to blood pressure (Szikora 2025).
  • Longevity interest: It rests on cardiovascular protection; no lifespan study in humans or animals was found.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the replicated human data are small randomized trials whose heart failure findings are contradicted by an independent randomized trial and whose blood pressure findings are inconsistent across trials.

Medium 🟩 🟩

Exercise Capacity and Symptoms in Chronic Heart Failure ⚠️ Conflicted

In people with NYHA class I–III heart failure on standard drugs, a Cochrane meta-analysis found better maximal workload and fewer symptoms such as breathlessness and fatigue (Pittler 2008). Contributing trials came from German groups such as Tauchert (Tauchert 2002) and Zapfe (Zapfe 2001), mostly testing one manufacturer’s extract, WS 1442. The independent HERB CHF trial (120 patients, 6 months) found no difference in walking distance, quality of life or exercise testing (Zick 2009). Net: modest gains in small, single-extract trials are not confirmed by the most rigorous independent trial.

Magnitude: Maximal workload 5.35 W more than placebo (95% CI (confidence interval, the range likely to contain the true effect) 0.71 to 10.00; 380 patients) and symptom score 5.47 points lower (95% CI −8.68 to −2.26; 239 patients) (Pittler 2008); six-minute walk distance not different from placebo (P (probability of a difference this large arising by chance) = 0.61) (Zick 2009).

Blood Pressure Reduction in Hypertension ⚠️ Conflicted

A 2025 meta-analysis pooled six placebo-controlled trials (428 adults with hypertension, 10 weeks to 6 months) from independent groups, including Walker in the UK and Asgary in Iran (Szikora 2025). Results are inconsistent: Walker’s diabetes trial lowered diastolic but not systolic pressure (Walker 2006), her pilot found no group difference (Walker 2002), Asgary used another species (Asgary 2004), and bias risk was mostly unclear. Its abstract prints the systolic upper bound as +1.59; the results give −1.59, used here. Net: a modest systolic reduction is probable but not consistently replicated.

Magnitude: Systolic pressure 6.65 mmHg lower than placebo (95% CI −11.72 to −1.59); diastolic pressure 7.19 mmHg lower, not significant (95% CI −15.17 to 0.79) (Szikora 2025).

Low 🟩

Cardiac Death and Sudden Cardiac Death ⚠️ Conflicted

In SPICE, 2,681 heart failure patients with left ventricular ejection fraction (share of blood pumped per beat) ≤35% took WS 1442 or placebo for 24 months; cardiac events and deaths did not differ (Holubarsch 2008). Net: the primary result is null; fewer sudden deaths in one subgroup is exploratory.

Magnitude: First cardiac event 27.9% vs 28.9% with placebo (HR (hazard ratio, the relative event rate over time) 0.95, 95% CI 0.82 to 1.10); sudden cardiac death in the ejection fraction ≥25% subgroup HR 0.59 (95% CI 0.37 to 0.94) (Holubarsch 2008).

LDL Cholesterol ⚠️ Conflicted

In 49 people with diabetes and coronary disease on statins (cholesterol-lowering drugs), Crataegus laevigata lowered LDL (low-density lipoprotein, the artery-clogging cholesterol) cholesterol within the group, but not versus placebo (Dalli 2011). In a meta-analysis, hawthorn-containing Chinese formulas (indirect) lowered LDL less than drugs (Zhou 2024). Net: no direct between-group benefit.

Magnitude: LDL cholesterol fell from 105 to 92.7 mg/dL over 6 months within the hawthorn group; the placebo-group figure is not reported, and the between-group difference was not significant (Dalli 2011).

Anxiety, Nervous Heart Complaints and Sleep ⚠️ Conflicted

The EMA accepts nervous heart complaints, mild stress and sleep on tradition alone (EMA monograph). Hawthorn 500 mg daily showed only a nonsignificant anxiety trend (Walker 2002); a larger manufacturer-run trial combining hawthorn, California poppy and magnesium was positive but indirect (Hanus 2004). Net: unproven for hawthorn alone.

Magnitude: In the combination trial, the Hamilton Anxiety Scale (a clinician-rated anxiety score) total fell 10.6 points vs 8.9 points with placebo (P = 0.005) (Hanus 2004); no outcome figure exists for hawthorn alone.

Skin Hydration ⭕️ Not Central to Health & Longevity

In 36 healthy adults, Chinese hawthorn (Crataegus pinnatifida) fruit powder for 6 months improved device-measured skin hydration; wrinkles and leukocyte telomere length (white-blood-cell chromosome-end length, an aging marker) did not change (Kim 2025). Species and plant part differ. This bears on skin appearance.

Magnitude: Hydration score change +1.71 vs −3.00 with placebo (P < 0.05; Cohen’s d (standardized effect size) 0.57) (Kim 2025).

Speculative 🟨

Endothelial Aging and Heart Muscle Protection

A review reports that WS 1442 delayed endothelial senescence (vessel-lining cell aging) and limited heart reperfusion injury (damage when blood flow returns) in laboratory and animal studies (Holubarsch 2018). The basis is mechanistic only.

Liver Fat Reduction

Hawthorn fruit extract reduced diet-induced fatty liver in mice and liver-cell models (Zhou 2026). The basis is animal and laboratory data only; no human liver trial of hawthorn alone exists.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist for common hawthorn. The only genotype analysis, in a Chinese hawthorn fruit trial, found larger skin effects in specific TERT (telomerase reverse transcriptase, the gene for the telomere-maintaining enzyme) genotypes (rs7705526 CC, rs2853669 AA), an exploratory finding (Kim 2025).
  • Baseline blood pressure: Trials pooled in a meta-analysis enrolled adults above 140/90 mmHg (Szikora 2025); a review reports that in rats the extract lowered high but not normal pressure (Holubarsch 2018), so little change is expected at normal readings.
  • Baseline heart function: In a Cochrane review, symptom benefits came mainly from trials in milder heart failure (Pittler 2008); in heart failure with reduced ejection fraction, neither SPICE (ejection fraction ≤35%) nor HERB CHF showed clinical benefit (Holubarsch 2008; Zick 2009).
  • Sex: No trial reported sex-specific efficacy; the blood pressure meta-analysis population was 44.8% women (Szikora 2025).
  • Age: Heart failure trials enrolled mainly older adults; the EMA uses identical dosing for adults and elderly people (EMA monograph). Data in healthy middle-aged adults are limited to small pilot trials, one co-authored by manufacturer staff (Niederseer 2019).
  • Pre-existing conditions: In type 2 diabetes treated with several drugs, diastolic pressure fell more than with placebo (Walker 2006); in diabetes with coronary disease, lipids did not differ from placebo (Dalli 2011).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no harm has been replicated in controlled trials from more than one independent group, and the largest randomized trial found adverse event rates equal to placebo.

Medium 🟥 🟥

No risk reaches Medium: the harm signals come from one small randomized trial outweighed by a much larger one, or from case reports, uncontrolled clinic records and regulator product testing.

Low 🟥

General Adverse Events ⚠️ Conflicted

Reported effects are dizziness, gastrointestinal upset, headache and palpitations, mostly mild across 24 studies in a systematic review (Daniele 2006). HERB CHF found more adverse events with hawthorn, mostly non-cardiac (Zick 2009); the much larger SPICE found no excess (Holubarsch 2008). Net: no excess in the strongest trial.

Magnitude: Any adverse event 67.0% with WS 1442 vs 68.3% with placebo, serious events 39.2% vs 41.1%, in SPICE as summarized in a review (Holubarsch 2018); any adverse event 60% vs 38% with placebo (P = 0.02) in HERB CHF (Zick 2009).

Early Heart Failure Worsening ⚠️ Conflicted

In a post hoc (decided after unblinding) HERB CHF analysis, WS 1442 users had more early heart failure progression, especially with ejection fraction ≤35% (Zick 2008). SPICE showed no such signal over 24 months, as summarized in a review (Holubarsch 2018). Net: an unconfirmed signal in severe disease.

Magnitude: Overall progression 46.6% vs 43.3% with placebo (OR (odds ratio, the relative odds of the event) 1.14, 95% CI 0.56 to 2.35); adjusted risk of early progression 6.4-fold higher (95% CI 1.5 to 26.5) (Zick 2008).

Adulterated or Misidentified Hawthorn Products

The U.S. Food and Drug Administration (FDA) found products labeled tejocote root (Mexican hawthorn, Crataegus mexicana) that contained toxic yellow oleander (FDA alert). A tejocote product caused vomiting, slow heart rate and heart block (impaired electrical conduction) (Palmer 2019). This concerns another species and plant part.

Magnitude: Not quantified in available studies. The evidence consists of regulator product testing and single case reports with no comparison group, which provide no denominator.

Bleeding with Anti-Clotting Drugs

At an anticoagulation clinic (2,788 warfarin users), hawthorn use accompanied raised INR (international normalized ratio, a clotting-time measure) in 11 patients and two bleeding hospitalizations (Al-Momany 2019). Extracts inhibit platelet clumping in laboratory and animal studies (Gao 2019; Shatoor 2012); a systematic review found two trial gastrointestinal hemorrhages (Daniele 2006).

Magnitude: Raised INR in 11 patients and two bleeding hospitalizations among 2,788 clinic patients, no control group; the clinic records give no count of hawthorn users and no comparison rate (Al-Momany 2019).

Speculative 🟨

Pregnancy and Breastfeeding

Safety in pregnancy and lactation has not been established, and the EMA does not recommend use (EMA monograph). The concern reflects absent data, with no isolated reports of harm.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic variant is known to change hawthorn’s risks, and the enzymes that metabolize its constituents have not been identified.
  • Baseline heart function: The early-worsening signal was concentrated in people with ejection fraction ≤35% (Zick 2008); people with milder or no heart failure carry no reported signal.
  • Baseline blood pressure and heart rate: Low resting pressure or a slow pulse leaves less margin for additive lowering with antihypertensive drugs (blood pressure-lowering medicines); inferred from hawthorn’s vessel-relaxing action, with no human data.
  • Sex: No sex-specific adverse event data exist; pregnancy and breastfeeding are the main female-specific considerations (EMA monograph).
  • Age: In SPICE, about 90% of patients took three or more cardioactive drugs without excess adverse events, as summarized in a review (Holubarsch 2018); falls and dizziness appear among events reported in a systematic review, which matters most at older ages (Daniele 2006).
  • Pre-existing conditions: Heart failure, arrhythmia and use of digoxin raise the stakes of any adulterated product, since a product sold as tejocote root caused digoxin-like toxicity and cross-reacted with a digoxin assay (Palmer 2019).

Key Interactions & Contraindications

Documented interactions:

  • Digoxin: In eight healthy volunteers, WS 1442 900 mg daily for 21 days did not change digoxin blood levels or clearance; no interaction found (Tankanow 2003). Routine digoxin level checks still apply.
  • Heart failure regimens (ACE inhibitors, which block angiotensin II formation, e.g., ramipril; beta-blockers, heart-rate-slowing drugs, e.g., metoprolol; diuretics, urine-increasing drugs, e.g., furosemide): Over 24 months in 2,681 patients, WS 1442 showed no interaction signal (Holubarsch 2008). Changes are coordinated with the prescriber.
  • Blood pressure and glucose-lowering drugs in type 2 diabetes (e.g., lisinopril, metformin): In people averaging 4.4 such drugs, no herb-drug interaction was found over 16 weeks; diastolic pressure fell slightly more than with placebo (Walker 2006). Home pressure checks detect it.
  • D-Camphor (fixed hawthorn berry–camphor drops, Korodin): In a meta-analysis of four trials, the combination raised systolic and diastolic pressure versus placebo, the opposite of hawthorn alone (Csupor 2019). Labels are checked for camphor when lower pressure is the aim.
  • Vitamin K antagonists (clot-preventing drugs that block vitamin K’s role in clotting; warfarin, acenocoumarol): In an anticoagulation clinic, hawthorn use accompanied raised INR in 11 warfarin users and two bleeding hospitalizations (Al-Momany 2019). INR checks after starting or stopping hawthorn detect the change.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Nitrates (vessel-widening angina drugs) and PDE5 inhibitors (erectile dysfunction drugs blocking phosphodiesterase type 5) (nitroglycerin, isosorbide mononitrate; sildenafil, tadalafil): Additive nitric oxide-mediated vessel relaxation could cause excessive pressure drops and fainting; inferred from eNOS activation. Staggered starts and standing pressure checks reduce the risk.
  • Antiplatelet drugs and direct anticoagulants (drugs that reduce blood clotting), including over-the-counter aspirin and NSAIDs (non-steroidal anti-inflammatory drugs) (clopidogrel, apixaban, rivaroxaban; aspirin, ibuprofen, naproxen): Additive bleeding tendency, inferred from laboratory and animal antiplatelet effects. Watching for bruising and pausing before surgery mitigate it.
  • Antiarrhythmic drugs (rhythm-control drugs such as amiodarone, sotalol, flecainide): Additive effects on heart rhythm, inferred from refractory-period prolongation in preclinical studies. An electrocardiogram after starting the combination checks for change.
  • Cardiac glycoside–containing herbs (plants with digoxin-like heart compounds, such as lily of the valley, foxglove, oleander): Additive effects on contractility and rhythm, potentially toxic, inferred from shared sodium-pump inhibition; any combination needs medical supervision.
  • Blood pressure–lowering supplements (hibiscus, garlic, coenzyme Q10): Additive pressure lowering and dizziness, inferred from overlapping vessel-relaxing actions. Home pressure checks after adding any of them detect it.
  • Over-the-counter decongestants (pseudoephedrine, phenylephrine): Vessel constriction may cancel hawthorn’s modest pressure lowering, inferred from opposing mechanisms; home pressure checks during decongestant use show it.
  • Alcohol: Additive vessel relaxation may increase dizziness on standing, inferred from mechanism; limiting intake around doses reduces it.

Populations who should avoid Common Hawthorn:

  • Known hypersensitivity to hawthorn — Contraindicated: the sole contraindication in the EMA herbal monograph (EMA monograph).
  • Pregnancy and breastfeeding — Avoid: safety has not been established, and the EMA does not recommend use (EMA monograph).
  • Children and adolescents: the EMA does not recommend use under 18 years for heart complaints or under 12 years for stress and sleep (EMA monograph).
  • Undiagnosed cardiac symptoms: the EMA restricts use to after serious heart conditions are excluded by a doctor, with medical review if symptoms persist beyond 2 weeks (EMA monograph).
  • Heart failure with ejection fraction ≤35% without cardiology supervision: heart failure progression risk was 3.2-fold higher than placebo (95% CI 1.3 to 8.3) in this subgroup (Zick 2008).
  • Users of tejocote root products — Avoid: the FDA found toxic yellow oleander in such products (FDA alert).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pharmacopoeial leaf-and-flower products: Choosing Crataegus monogyna or C. laevigata leaf-and-flower extracts, never “tejocote root”, avoids the yellow oleander adulteration found by the FDA (FDA alert).
  • Medical evaluation first: Ruling out heart failure, arrhythmia and coronary disease before self-use prevents hawthorn from masking serious disease; the EMA calls for medical review if symptoms persist beyond 2 weeks (EMA monograph).
  • Gradual start: Starting at half the target dose (e.g., 450 mg daily) for 1–2 weeks limits dizziness and gastrointestinal upset, the most reported adverse events in a systematic review (Daniele 2006).
  • Home pressure and pulse log: Twice-weekly readings for 4 weeks alongside antihypertensives detect additive lowering; readings below 90/60 mmHg, the National Heart, Lung, and Blood Institute (NHLBI) low blood pressure cutoff (NHLBI page), or standing dizziness prompt dose review.
  • Supervised use in heart failure: Daily weight and symptom tracking during the first 2 months, with the cardiologist informed, targets the early-worsening signal seen with ejection fraction ≤35% (Zick 2008).
  • Laboratory disclosure for digoxin users: Telling the laboratory about hawthorn use guards against misread digoxin results; tejocote root cross-reacted with a digoxin assay (Palmer 2019).
  • INR checks for warfarin users: An INR test 1–2 weeks after starting or stopping hawthorn detects the clotting-time rises and bleeding risk seen in an anticoagulation clinic (Al-Momany 2019).
  • Pre-surgery pause: Stopping 1–2 weeks before surgery or dental extraction addresses the antiplatelet bleeding risk.
  • Camphor-free products: Avoiding hawthorn–camphor drops in hypertension prevents the blood pressure increases this combination produced in a meta-analysis (Csupor 2019).

Therapeutic Protocol

Timing, cycling and titration steps below reflect common practice unless cited; sources differ on dose, and each value is given with its source.

  • Standardized extract for heart failure: WS 1442 450 mg twice daily (Holubarsch 2008; Zick 2009); 1,800 mg daily outperformed 900 mg on workload in class III disease (Tauchert 2002). Popularized through Schwabe’s Crataegutt (Holubarsch 2018).
  • Blood pressure regimens: Trials pooled in a meta-analysis used 250–1,200 mg daily (Szikora 2025); the diabetes trial used 1,200 mg daily for 16 weeks alongside medication (Walker 2006).
  • Traditional EMA regimens: Tea of 1–2 g dried leaf and flower in 150 mL boiling water up to 4 times daily (maximum 6 g), or powdered herb 570–1,750 mg daily (EMA monograph).
  • Herbalist approach: Christopher Hobbs describes liquid extract taken for at least 3 months, up to several years (Hobbs article).
  • Time of day: No study compared timing; trials split doses between morning and evening, and the EMA tea regimen spreads intake across the day.
  • Half-life: No human half-life has been published (Holubarsch 2018); controlled trials dosed twice daily, which is the tested schedule.
  • Single versus split dosing: Split twice-daily dosing is the tested pattern (Tankanow 2003); single-dose data are limited to an electrocardiogram safety study showing no change (Trexler 2018).
  • Genetic polymorphisms: No variant guides dose choice; the enzymes handling hawthorn’s constituents are uncharacterized.
  • Sex: Trials in a blood pressure meta-analysis used identical doses in men and women, and no sex-specific dosing data exist (Szikora 2025).
  • Age: The EMA gives identical doses for adults and elderly people (EMA monograph); heart failure trials enrolled mainly older adults.
  • Baseline blood pressure: Trials pooled in a meta-analysis enrolled adults above 140/90 mmHg (Szikora 2025); no blood pressure trial data exist for people with normal readings.
  • Pre-existing conditions: In a Cochrane review, most heart failure trials tested hawthorn as an add-on to standard drugs, not a replacement (Pittler 2008).

Discontinuation & Cycling

  • Lifelong or short-term: No defined endpoint exists; heart failure use ran continuously for up to 24 months (Holubarsch 2008), while EMA traditional use calls for review if symptoms persist beyond 2 weeks (EMA monograph).
  • Withdrawal effects: None reported in trials; the EMA monograph lists no known undesirable effects (EMA monograph).
  • Tapering: No tapering protocol exists; in heart failure, stopping is coordinated with the cardiologist so that symptom changes are attributed correctly.
  • Cycling: Cycling has not been studied and no tolerance has been described; continuous daily use is the tested pattern.

Sourcing and Quality

  • Plant part: Most clinical evidence uses leaf-and-flower extracts; berry preparations, common in U.S. stores, have far fewer trials, per a systematic review (Daniele 2006).
  • Species: The EMA lists Crataegus monogyna, C. laevigata (or their hybrids), C. pentagyna and C. azarolus as sources of hawthorn leaf and flower (EMA monograph); C. pinnatifida and C. mexicana products are different species.
  • Standardization: WS 1442 is a 45% ethanol dry extract adjusted to 17.3–20.1% oligomeric procyanidins (Holubarsch 2018); labels stating procyanidin content allow comparison with trial doses.
  • Adulteration: The FDA found yellow oleander in products sold as tejocote root, often marketed for weight loss (FDA alert); “hawthorn root” weight-loss products are a warning sign.
  • Third-party testing: ConsumerLab has published no hawthorn product test; a USP (United States Pharmacopeia) or NSF (an independent product-certification organization) seal indicates independent identity and contaminant testing where available.
  • Reputable brands: Crataegutt (Dr. Willmar Schwabe) contains WS 1442, the extract used in SPICE and HERB CHF, per a review (Holubarsch 2018).

Practical Considerations

  • Time to effect: In a meta-analysis, blood pressure trials lasted 10 weeks to 6 months, with effects measured after 2–6 months (Szikora 2025); a heart failure trial found workload gains at 16 weeks (Tauchert 2002); herbalists expect at least 3 months (Hobbs article).
  • Common pitfalls: Substituting hawthorn for standard heart drugs; buying berry or tejocote products while expecting leaf-and-flower trial results; using hawthorn–camphor drops for high blood pressure; assuming no interaction with nitrates or antiplatelet or anticoagulant drugs.
  • Regulatory status: In the U.S., hawthorn is a dietary supplement not FDA-reviewed before sale, per the National Center for Complementary and Integrative Health (NCCIH fact sheet); in the European Union it is a traditional herbal medicine, with a 2025 draft monograph revision (EMA monograph).
  • Cost and accessibility: Hawthorn is inexpensive and widely available; generic blood pressure drugs are also inexpensive, so payers have no strong cost incentive either way, and research funding has come mainly from one extract manufacturer.

Interaction with Foundational Habits

  • Sleep: Possibly supportive, indirect. The EMA accepts traditional use to aid sleep (EMA monograph), but no controlled sleep trial of hawthorn alone exists. No sleep disruption has been reported; late-evening tea adds nighttime fluid.
  • Nutrition: No known nutrient depletion. Hawthorn fruit is eaten in jams and, as Chinese hawthorn, in snacks; a sweetened hawthorn fruit drink showed no metabolic benefit over a sugar-matched placebo (Zeng 2024). Taking extracts with meals may reduce gastrointestinal upset.
  • Exercise: No blunting, no added benefit. In overweight adults, Nordic walking (brisk walking with poles) improved exercise capacity while WS 1442 did not, and endothelial function improved with either (Niederseer 2019). In heart failure, a Cochrane review reported modest workload gains (Pittler 2008).
  • Stress management: Possibly supportive, unproven. Hawthorn has traditional use for mild stress (EMA monograph); a pilot showed only a nonsignificant anxiety trend (Walker 2002). No cortisol data exist, and it complements rather than replaces behavioral stress techniques.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a seated blood pressure and resting pulse (several home readings averaged), a review of current drugs for nitrates, antiplatelet or anticoagulant drugs, rhythm-control drugs and digoxin, and, for people with heart failure, a recent ejection fraction and natriuretic peptide (a blood marker of heart strain) result set reference points.

Ongoing monitoring: Blood pressure and pulse are rechecked at 2 and 4 weeks, then every 3 months, at the same time of day before the dose. People with heart failure track weight and symptoms weekly for the first 2 months and repeat the natriuretic peptide at 3 months, then every 6–12 months. Digoxin users keep their scheduled levels. Success is a sustained fall in home systolic pressure, or better exertion tolerance in heart failure, without new dizziness, slowed pulse or swelling; no change after 3 months suggests no response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <130/80 mmHg (ACC/AHA 2017 guideline treatment target) Expected to change Seated, after 5 minutes’ rest, before the morning dose; source: Whelton 2018, from the American College of Cardiology (ACC) and American Heart Association (AHA), professional bodies whose clinician members earn revenue from treating hypertension, not from hawthorn; conventional reference range: normal <120/80 mmHg (Whelton 2018)
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: unexpected slowing stops use Measured with blood pressure; severe heart-rate slowing occurred in a reported tejocote poisoning (Palmer 2019)
Serum digoxin (digoxin users only) 0.5–2.0 ng/mL therapeutic range (as stated by Palmer 2019) Safety check: unexpected change prompts review Trough sample before the daily dose; hawthorn did not alter digoxin levels (Tankanow 2003), but tejocote cross-reacted with an assay (Palmer 2019); no population reference range applies to a drug level
NT-proBNP (heart failure only) No established target; track change from own baseline Safety check: a rise signals worsening heart failure N-terminal pro-B-type natriuretic peptide, a blood marker of heart strain; same laboratory each time; relevant to the early-worsening signal (Zick 2008)

Qualitative markers:

  • Exercise tolerance, such as stairs or walking distance before breathlessness
  • Fatigue and breathlessness during daily activity
  • Frequency of palpitations
  • Dizziness on standing
  • Ankle swelling and day-to-day weight stability
  • Sleep quality and perceived stress

Emerging Research

  • Ketone and hawthorn pilot in heart failure (NCT07166965): 45 patients with class II–III heart failure receive hawthorn 2,000 mg daily, ketones or placebo for 8 weeks; endpoints are peak oxygen uptake and MRI (magnetic resonance imaging, a magnetic-field heart scan) ejection fraction; enrolling, completion 2029. Positive: partly revives functional benefit; null: weakens it further.
  • EMA monograph revision: In 2025 the EMA released a draft revised monograph covering C. monogyna, C. laevigata, their hybrids, C. pentagyna and C. azarolus (EMA monograph); the final text may change the regulated indications or safety wording.
  • Independent blood pressure trials: The 2025 meta-analysis calls for larger trials by independent groups with standard endpoints (Szikora 2025); a large positive trial could strengthen the blood pressure grade, and a null one would weaken it to Low.
  • Comparative ranking in heart failure: A 2026 network meta-analysis ranked another plant extract first on each of the four outcomes summarized, never hawthorn, and cautioned that some extracts had few studies (Tang 2026); this weakens the case for hawthorn as the preferred botanical option.
  • Completed trial without results: A Taiwanese study of hawthorn 3 g daily on lipids in people taking antipsychotics (drugs used to treat psychosis, as in schizophrenia) completed in 2014, with no results posted (NCT03663465).
  • Unresolved safety signal: No trial has re-tested the early heart failure worsening seen in a post hoc analysis (Zick 2008); confirmation would weaken the case in severe heart failure, while refutation would strengthen it.

Conclusion

Common hawthorn is a European shrub whose leaf-and-flower extracts have a long history as a heart tonic and are sold today as supplements and, in Europe, as traditional herbal medicines. For health-focused adults without heart disease, most of the evidence comes from people who are sicker than they are.

The strongest human data concern people with existing heart failure. Small trials found better exercise tolerance and fewer symptoms in mild disease, but the most careful independent trial found no functional benefit, and the largest trial did not reduce heart events or deaths. In people with raised blood pressure, pooled small trials point to a modest fall in the upper reading, with inconsistent results. Effects on cholesterol, anxiety, sleep, blood vessel aging and skin remain unproven in people.

Hawthorn itself appears well tolerated: in the largest trial, side effects occurred no more often than with a placebo, although one smaller trial raised an unconfirmed concern about early worsening in severe heart failure. The main practical hazards lie elsewhere: products sold as Mexican hawthorn root have been found to contain a poisonous plant, and hawthorn could add to the effects of heart, blood pressure and anti-clotting drugs.

Much of the research tested a single company’s extract, the largest trial’s investigators were paid by that company, and independent trials are few and small. Whether hawthorn benefits people without heart disease, or affects how long anyone lives, remains uncertain.

Top - Benefits - Risks - Protocol